Literature DB >> 33785765

SARS-CoV-2 in severe COVID-19 induces a TGF-β-dominated chronic immune response that does not target itself.

Marta Ferreira-Gomes1, Andrey Kruglov1,2,3, Pawel Durek1, Frederik Heinrich1, Caroline Tizian4,5,6, Gitta Anne Heinz1, Anna Pascual-Reguant1,7, Weijie Du1, Ronja Mothes1,8, Chaofan Fan1, Stefan Frischbutter9, Katharina Habenicht10, Lisa Budzinski1, Justus Ninnemann1, Peter K Jani1, Gabriela Maria Guerra1, Katrin Lehmann1, Mareen Matz11, Lennard Ostendorf1,8, Lukas Heiberger1, Hyun-Dong Chang1,12, Sandy Bauherr1, Marcus Maurer9, Günther Schönrich13, Martin Raftery13, Tilmann Kallinich1,5,14, Marcus Alexander Mall5,14,15, Stefan Angermair16, Sascha Treskatsch16, Thomas Dörner1,7, Victor Max Corman13, Andreas Diefenbach4,5,6, Hans-Dieter Volk11,17, Sefer Elezkurtaj18, Thomas H Winkler10, Jun Dong1, Anja Erika Hauser1,7, Helena Radbruch8, Mario Witkowski4,5,6, Fritz Melchers1, Andreas Radbruch1, Mir-Farzin Mashreghi19,20.   

Abstract

The pathogenesis of severe COVID-19 reflects an inefficient immune reaction to SARS-CoV-2. Here we analyze, at the single cell level, plasmablasts egressed into the blood to study the dynamics of adaptive immune response in COVID-19 patients requiring intensive care. Before seroconversion in response to SARS-CoV-2 spike protein, peripheral plasmablasts display a type 1 interferon-induced gene expression signature; however, following seroconversion, plasmablasts lose this signature, express instead gene signatures induced by IL-21 and TGF-β, and produce mostly IgG1 and IgA1. In the sustained immune reaction from COVID-19 patients, plasmablasts shift to the expression of IgA2, thereby reflecting an instruction by TGF-β. Despite their continued presence in the blood, plasmablasts are not found in the lungs of deceased COVID-19 patients, nor does patient IgA2 binds to the dominant antigens of SARS-CoV-2. Our results thus suggest that, in severe COVID-19, SARS-CoV-2 triggers a chronic immune reaction that is instructed by TGF-β, and is distracted from itself.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33785765     DOI: 10.1038/s41467-021-22210-3

Source DB:  PubMed          Journal:  Nat Commun        ISSN: 2041-1723            Impact factor:   14.919


  54 in total

Review 1.  Competence and competition: the challenge of becoming a long-lived plasma cell.

Authors:  Andreas Radbruch; Gwendolin Muehlinghaus; Elke O Luger; Ayako Inamine; Kenneth G C Smith; Thomas Dörner; Falk Hiepe
Journal:  Nat Rev Immunol       Date:  2006-09-15       Impact factor: 53.106

2.  Direct evidence that gamma 1 and gamma 3 switching in human B cells is interleukin-10 dependent.

Authors:  S Fujieda; A Saxon; K Zhang
Journal:  Mol Immunol       Date:  1996-12       Impact factor: 4.407

3.  Generation of migratory antigen-specific plasma blasts and mobilization of resident plasma cells in a secondary immune response.

Authors:  Marcus Odendahl; Henrik Mei; Bimba F Hoyer; Annett M Jacobi; Arne Hansen; Gwendolin Muehlinghaus; Claudia Berek; Falk Hiepe; Rudi Manz; Andreas Radbruch; Thomas Dörner
Journal:  Blood       Date:  2004-10-26       Impact factor: 22.113

4.  Cutting edge: IL-21 is a switch factor for the production of IgG1 and IgG3 by human B cells.

Authors:  Jérôme Pène; Jean-François Gauchat; Sandrine Lécart; Elodie Drouet; Paul Guglielmi; Vera Boulay; Adriana Delwail; Don Foster; Jean-Claude Lecron; Hans Yssel
Journal:  J Immunol       Date:  2004-05-01       Impact factor: 5.422

5.  TGF-beta 1 induces germ-line transcripts of both IgA subclasses in human B lymphocytes.

Authors:  K B Islam; L Nilsson; P Sideras; L Hammarström; C I Smith
Journal:  Int Immunol       Date:  1991-11       Impact factor: 4.823

6.  Regulation of C gamma subclass germ-line transcripts in human peripheral blood B cells.

Authors:  A Kitani; W Strober
Journal:  J Immunol       Date:  1993-10-01       Impact factor: 5.422

7.  HLA-DRhigh/CD27high plasmablasts indicate active disease in patients with systemic lupus erythematosus.

Authors:  A M Jacobi; H Mei; B F Hoyer; I M Mumtaz; K Thiele; A Radbruch; G-R Burmester; F Hiepe; T Dörner
Journal:  Ann Rheum Dis       Date:  2010-01       Impact factor: 19.103

Review 8.  B Cell Responses: Cell Interaction Dynamics and Decisions.

Authors:  Jason G Cyster; Christopher D C Allen
Journal:  Cell       Date:  2019-04-18       Impact factor: 41.582

Review 9.  B cell responses to influenza infection and vaccination.

Authors:  Christopher Chiu; Ali H Ellebedy; Jens Wrammert; Rafi Ahmed
Journal:  Curr Top Microbiol Immunol       Date:  2015       Impact factor: 4.291

10.  Severe COVID-19: what have we learned with the immunopathogenesis?

Authors:  Bruno Bordallo; Mozart Bellas; Arthur Fernandes Cortez; Matheus Vieira; Marcelo Pinheiro
Journal:  Adv Rheumatol       Date:  2020-09-22
View more
  41 in total

1.  Exposure modality influences viral kinetics but not respiratory outcome of COVID-19 in multiple nonhuman primate species.

Authors:  Alyssa C Fears; Brandon J Beddingfield; Nicole R Chirichella; Nadia Slisarenko; Stephanie Z Killeen; Rachel K Redmann; Kelly Goff; Skye Spencer; Breanna Picou; Nadia Golden; Cecily C Midkiff; Duane J Bush; Luis M Branco; Matthew L Boisen; Hongmei Gao; David C Montefiori; Robert V Blair; Lara A Doyle-Meyers; Kasi Russell-Lodrigue; Nicholas J Maness; Chad J Roy
Journal:  PLoS Pathog       Date:  2022-07-05       Impact factor: 7.464

2.  Gene Networks of Hyperglycemia, Diabetic Complications, and Human Proteins Targeted by SARS-CoV-2: What Is the Molecular Basis for Comorbidity?

Authors:  Olga V Saik; Vadim V Klimontov
Journal:  Int J Mol Sci       Date:  2022-06-29       Impact factor: 6.208

Review 3.  Gal-3BP in Viral Infections: An Emerging Role in Severe Acute Respiratory Syndrome Coronavirus 2.

Authors:  Valentina Gallo; Alyexandra Arienzo; Stefano Iacobelli; Valentina Iacobelli; Giovanni Antonini
Journal:  Int J Mol Sci       Date:  2022-06-30       Impact factor: 6.208

4.  Integrin/TGF-β1 Inhibitor GLPG-0187 Blocks SARS-CoV-2 Delta and Omicron Pseudovirus Infection of Airway Epithelial Cells In Vitro, Which Could Attenuate Disease Severity.

Authors:  Kelsey E Huntington; Lindsey Carlsen; Eui-Young So; Matthias Piesche; Olin Liang; Wafik S El-Deiry
Journal:  Pharmaceuticals (Basel)       Date:  2022-05-17

5.  Aging-related cell type-specific pathophysiologic immune responses that exacerbate disease severity in aged COVID-19 patients.

Authors:  Yuan Hou; Yadi Zhou; Lara Jehi; Yuan Luo; Michaela U Gack; Timothy A Chan; Haiyuan Yu; Charis Eng; Andrew A Pieper; Feixiong Cheng
Journal:  Aging Cell       Date:  2022-01-12       Impact factor: 11.005

6.  In silico analysis suggests the RNAi-enhancing antibiotic enoxacin as a potential inhibitor of SARS-CoV-2 infection.

Authors:  Amirhossein Ahmadi; Sharif Moradi
Journal:  Sci Rep       Date:  2021-05-13       Impact factor: 4.379

Review 7.  Antiviral Activities of Group I Innate Lymphoid Cells.

Authors:  Ramon A Lujan; Sophia M Vrba; Heather D Hickman
Journal:  J Mol Biol       Date:  2021-09-22       Impact factor: 5.469

Review 8.  SARS-CoV-2 Portrayed against HIV: Contrary Viral Strategies in Similar Disguise.

Authors:  Ralf Duerr; Keaton M Crosse; Ana M Valero-Jimenez; Meike Dittmann
Journal:  Microorganisms       Date:  2021-06-27

Review 9.  TLRs in COVID-19: How they drive immunopathology and the rationale for modulation.

Authors:  F Linzee Mabrey; Eric D Morrell; Mark M Wurfel
Journal:  Innate Immun       Date:  2021-11-20       Impact factor: 2.951

10.  Integrin/TGF-β1 inhibitor GLPG-0187 blocks SARS-CoV-2 Delta and Omicron pseudovirus infection of airway epithelial cells which could attenuate disease severity.

Authors:  Kelsey E Huntington; Lindsey Carlsen; Eui-Young So; Matthias Piesche; Olin Liang; Wafik S El-Deiry
Journal:  medRxiv       Date:  2022-01-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.